Press Releases2017-09-13T20:17:34+00:00

Press Releases

Positive Growth of Eli Lilly’s Taltz and Stabilization of Novartis’ Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift

Cosentyx’s first-to-market status in psoriasis, psoriatic arthritis, and ankylosing spondylitis has historically provided the brand with a competitive edge over in-class rival, Taltz, though recent studies conducted by Spherix Global Insights indicate changes are afootEXTON, Pa., October 10, 2019 /PRNewswire/ — Novartis’ Cosentyx was first approved by the FDA for the treatment of psoriasis in January 2015, followed by a label extension for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) a year later – snagging the first-to-market IL-17 inhibitor status in all three markets. With Eli Lilly’s IL-17 competitor, Taltz, entering the psoriasis market in March 2016 and the PsA [...]

October 10, 2019|

Benefitting From Expanded Access in Europe, Roche’s Ocrevus is on Track to Displace Biogen’s Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months

Italian and Spanish neurologists’ recent embrace of Merck KGaA’s Mavenclad, combined with a shift from Sanofi’s Lemtrada in the UK to Mavenclad, has helped boost share of the high-efficacy oral therapy, according to the 5th wave of the twice-yearly Spherix Global Insights report

October 7, 2019|

Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly’s Third-to-Market Emgality to Second Place in the Anti-CGRP Class ― Surpassing Teva’s Ajovy

Allergan’s Botox appears indifferent to the chatter surrounding the anti-CGRP class launch, benefitting from high patient awareness and switch business opportunities following anti-CGRP discontinuations, according to the fifth wave of the quarterly Spherix Global Insights series  EXTON, Pa., September 26, 2019 ― Nine months post launch, specialists’ self-reported share for Eli Lilly’s Emgality has surpassed (for the first time) that of Teva’s Ajovy among patients treated with a preventive therapy for migraine. While Amgen/Novartis’ Aimovig retains its class-leading share, data from 100 neurologists and migraine specialists surveyed in August for the current wave of the Spherix’s RealTime Dynamix™: Migraine [...]

September 26, 2019|

US Nephrologists Beginning to Trial AstraZeneca’s LOKELMA (zirconium sodium cyclosilicate) but Unclear on Differentiation from Vifor/Relypsa’s VELTASSA (patiromer FOS)

According to Spherix Global Insights, nephrologists surveyed in August report increased promotion and associated familiarity with Lokelma but express concerns about potential effects of sodium content. EXTON, Pa., / September 17, 2019 / PRNewswire – After two Complete Response Letters resulting in lengthy approval delays, AstraZeneca was finally able to introduce Lokelma, its novel treatment for hyperkalemia, to the US market earlier this year.  Lokelma was acquired from ZS Pharma in 2015 for $2.7 billion. In the latest quarterly wave of research with US nephrologists (n=105), which has been on-going since Q1 2016, participants were surveyed about their use [...]

September 17, 2019|

Novartis’ Cosentyx and Pfizer’s Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights

While the alternate mechanism of action agents are becoming increasingly popular in the second- or later-lines of therapy, they are also forfeiting a substantial amount of potential share EXTON, Pa., September 13, 2019 /PRNewswire/ — The fourth annual patient chart audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in PsA (US) service includes the feedback of 192 US rheumatologists who profiled 994 psoriatic arthritis (PsA) patients recently switched from one biologic/small molecule agent to another. As witnessed in the past several years, the percent of patients being switched from one TNF inhibitor to another has decreased from the prior [...]

September 13, 2019|

Unimpeded by Allergan’s Botox Dominance, Amgen/Novartis’ Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of

Teva’s Ajovy may be most at risk by the future availability of orally dosed anti-CGRP therapies, including Biohaven’s rimegepant and Allergan’s atogepant, while Allergan’s Botox will remain insulated from anti-CGRP class pressure, according to the inaugural Spherix Global Insights audit of the US migraine prevention market EXTON, Pa., September 11, 2019 ― Contributing physicians appear to underestimate their use of the anti-calcitonin gene-related peptide (CGRP) therapies in patients with episodic migraine. Neurologists and migraine specialists self-reported that less than half of their patients currently on Amgen/Novartis’ Aimovig, Teva’s Ajovy, or Eli Lilly’s Emgality were diagnosed with episodic migraine at [...]

September 11, 2019|